Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial

To evaluate the clinical efficacy of continuing cetuximab vs bevacizumab plus chemotherapy crossover after first progression to cetuximab regimen in wild-type KRAS, NRAS and BRAF V600E mCRC, we conducted this prospective, open-label and randomized phase 2 trial in three cancer centers from Oct 1, 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Danyang, Wang, Feng, Xu, Shuning, Li, Ke, Meng, Xiangrui, Huang, Yangyang, Ma, Ning, Qiao, Lei, Kuang, Gaizhen, Chen, Jinghong, Liu, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317523/
https://www.ncbi.nlm.nih.gov/pubmed/34335943
http://dx.doi.org/10.7150/jca.60014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317523/
https://www.ncbi.nlm.nih.gov/pubmed/34335943
http://dx.doi.org/10.7150/jca.60014

Ejemplares similares